TFAP2E-DKK4 and chemoresistance in colorectal cancer by Ebert, Matthias P A et al.
original article
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 366;1 nejm.org january 5, 201244
TFAP2E–DKK4 and Chemoresistance 
in Colorectal Cancer
Matthias P.A. Ebert, M.D., Marc Tänzer, M.A., Benjamin Balluff, M.Sc.,  
Elke Burgermeister, Ph.D., Antje Karen Kretzschmar, Ph.D., David J. Hughes, Ph.D.,  
Reimo Tetzner, Ph.D., Catherine Lofton-Day, Ph.D., Robert Rosenberg, M.D.,  
Anke C. Reinacher-Schick, M.D., Karsten Schulmann, M.D., Andrea Tannapfel, M.D., 
Ralf Hofheinz, M.D., Christoph Röcken, M.D., Gisela Keller, Ph.D., Rupert Langer, M.D., 
Katja Specht, M.D., Rainer Porschen, M.D., Jan Stöhlmacher-Williams, M.D.,  
Tibor Schuster, Ph.D., Philipp Ströbel, M.D., and Roland M. Schmid, M.D.
From the Department of Medicine II 
(M.P.A.E., E.B.), Department of Medicine 
III (R.H.), and Institute of Pathology (P.S.), 
Universitätsmedizin Mannheim, Ruprecht-
Karls-Universität Heidelberg, Mannheim; 
the Department of Medicine II (M.T., B.B., 
A.K.K., R.M.S.), Chirurgische Klinik und Poli-
klinik (R.R.), Institute of Pathology (G.K., 
R.L., K. Specht), and Institute of Medical 
Statistics and Epidemiology (T.S.), Klinikum 
Rechts der Isar, Technische Universität; 
and the Institute of Pathology, Technische 
Universi tät München, and Institute of Pa-
thology, Helmholtz Zentrum München, 
German Research Center for Environmen-
tal Health (B.B.) — all in Munich; the 
 Department of Medicine, Knapp schafts-
krankenhaus (A.C.R.-S., K. Schul mann), and 
the Department of Pathol ogy (A.T.), Ruhr 
Universität, Bochum; the Institute of Pa-
thology, Christian-Albrechts-Universität, 
Kiel (C.R.); the Department of Medicine, 
Bremen-Ost Hospital, Bremen (R.P.); and 
the Department of Medicine I, University 
Hospital, Technische Universität, Dresden 
(J.S.-W.) — all in Germany; the Department 
of Physiology and Medical Physics, Centre 
for Systems Medicine, Royal College of Sur-
geons of Ireland, Dublin (D.J.H.); and Epi-
genomics, Berlin (R.T.) and Seattle (C.L.-D.). 
Address reprint requests to Dr.  Ebert at 
the Department of Medicine II, Universi-
täts medizin Mann heim, Ruprecht-Karls-
Universität Heidelberg, Theodor-Kutzer-
Ufer 1-3, D-68167 Mann heim, Germany, 
or at matthias.ebert@umm.de.
N Engl J Med 2012;366:44-53.
Copyright © 2012 Massachusetts Medical Society.
A bs tr ac t
BACKGROUND
Chemotherapy for advanced colorectal cancer leads to improved survival; however, 
predictors of response to systemic treatment are not available. Genomic and epi-
genetic alterations of the gene encoding transcription factor AP-2 epsilon (TFAP2E) 
are common in human cancers. The gene encoding dickkopf homolog 4 protein 
(DKK4) is a potential downstream target of TFAP2E and has been implicated in chemo-
therapy resistance. We aimed to further evaluate the role of TFAP2E and DKK4 as pre-
dictors of the response of colorectal cancer to chemotherapy.
METHODS
We analyzed the expression, methylation, and function of TFAP2E in colorectal-
cancer cell lines in vitro and in patients with colorectal cancer. We examined an 
initial cohort of 74 patients, followed by four cohorts of patients (total, 220) un-
dergoing chemotherapy or chemoradiation.
RESULTS
TFAP2E was hypermethylated in 38 of 74 patients (51%) in the initial cohort. Hyper-
methylation was associated with decreased expression of TFAP2E in primary and 
metastatic colorectal-cancer specimens and cell lines. Colorectal-cancer cell lines 
overexpressing DKK4 showed increased chemoresistance to fluorouracil but not 
irinotecan or oxaliplatin. In the four other patient cohorts, TFAP2E hypermethyl-
ation was significantly associated with nonresponse to chemotherapy (P<0.001). 
Conversely, the probability of response among patients with hypomethylation was 
approximately six times that in the entire population (overall estimated risk ratio, 
5.74; 95% confidence interval, 3.36 to 9.79). Epigenetic alterations of TFAP2E were 
independent of mutations in key regulatory cancer genes, microsatellite instability, 
and other genes that affect fluorouracil metabolism.
CONCLUSIONS
TFAP2E hypermethylation is associated with clinical nonresponsiveness to chemo-
therapy in colorectal cancer. Functional assays confirm that TFAP2E-dependent resis-
tance is mediated through DKK4. In patients who have colorectal cancer with TFAP2E 
hypermethylation, targeting of DKK4 may be an option to overcome TFAP2E-mediated 
drug resistance. (Funded by Deutsche Forschungsgemeinschaft and others.)
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The treatment options and prognosis for patients with advanced colorectal can-cer have improved through the development 
of novel drugs.1,2 However, studies of the molec-
ular biology of cancer initiation and progression 
have so far provided scant knowledge of the mo-
lecular mechanisms contributing to chemotherapy 
resistance.2
Epigenetic alterations underlying the patho-
genesis of colorectal cancer have been reported by 
several groups.3 These alterations include hypo-
methylation and hypermethylation of DNA as well 
as histone modifications, all of which have a pro-
found effect on transcriptional gene regulation. 
The role of these molecular alterations in response 
prediction and treatment resistance are far less 
well known.4
The AP-2 transcription factor family has five 
members and plays an important role in both 
developmental biology and cancer biology.5 The 
gene encoding transcription factor AP-2 epsilon 
(TFAP2E) is located on chromosome 1p34, a region 
deleted in several cancers, including colorectal 
cancer.6 TFAP2E has two cytosine–phosphate–
guanine (CpG) islands, underscoring the poten-
tial for regulation of gene expression by means 
of CpG hypermethylation. In this study, we ana-
lyzed the role of TFAP2E in the biologic charac-
teristics of colorectal cancer.
Me thods
Patients and Tissue Samples
We obtained samples from patients undergoing 
surgery or chemotherapy at the University Hos-
pitals in Munich, Mannheim, Bochum, Berlin, 
Kiel, and Dresden (all in Germany). The re-
sponse of colon cancer to chemotherapy was 
 assessed according to Response Evaluation Cri-
teria in Solid Tumors (RECIST) criteria (ver-
sion 1.1)7 (see the Supplementary Appendix, 
available with the full text of this article at 
NEJM.org); the response of rectal cancer to 
chemoradiation was assessed on the basis of his-
tologic characteristics, as previously described.8 
Written informed consent was obtained from 
all patients before enrollment in the clinical 
trial (study protocol, in German, available at 
NEJM.org). Analysis of tissue samples from can-
cer patients was approved by the human sub-
jects committee of the Technische Universität 
München.
Cell Culture
The colon-cancer cell lines LoVo and DLD-1 were 
obtained from the Deutsche Sammlung von Mikro-
organismen und Zellkulturen; the lines SW480, 
HT-29, HCT-116, and Caco-2 were obtained from 
the American Type Culture Collection. Cells were 
cultured in standard medium and treated with 
aza-2-deoxycytidine or chemotherapeutic agents 
as described in the Supplementary Appendix.
DNA Analysis
Genomic DNA samples were analyzed with the 
use of the MethyLight technique9 or methylation-
sensitive high-resolution melting10 as previously 
described, after being treated according to the 
manufacturer’s instructions (Qiagen). The extent 
of methylation at a specific locus was measured 
as the ratio of (methylation of the gene ÷ methyl-
ation of beta-actin) for the sample to that for SssI-
treated genomic DNA, multiplied by 100. This for-
mula determines the percentage of the reference 
material that is methylated.9 Cutoff values per-
mitting the clearest discrimination between non-
neoplastic mucosal samples and tumor samples 
were determined by means of receiver-operating-
characteristic analysis.
Expression Microarray and Verification  
of Target Candidates
The clones pTFAP2E-pTarget and pTarget SW480 
were used in global-expression analysis with 
the use of a microarray (Human Gene 1.0 ST 
Expression Array, Affymetrix), according to the 
manufacturer’s protocol. Genes with a change 
in expression by more than a factor of 3 were veri-
fied by means of quantitative reverse-transcriptase–
polymerase-chain-reaction (RT-PCR) assay. Data 
obtained from the microarray have been depos-
ited at the Gene Expression Omnibus (www.ncbi 
.nlm.nih.gov/geo, accession number 15902739) 
(see the Supplementary Appendix).
Reporter and Expression Vectors
The full-length TFAP2E coding sequence was am-
plified from SW480 cells and cloned, with and 
without the FLAG epitope (forming pTFAP2E and 
pTFAP2eFlag, respectively), into the pTarget vec-
tor (Promega) according to the manufacturer’s 
instructions. The promoter sequence of the gene 
encoding dickkopf homolog 4 protein (DKK4) was 
cloned into the pGL3 basic vector (Promega): pGL3-
DKK4-1kb (with a 1-kb insert starting 1 kb upstream 
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of the transcription start site). The pRL-TK report-
er plasmid (Promega) was used as an internal-
control reporter vector. Full-length DKK4-CDS 
plasmid (pcDNA3-Dkk4) and the DKK4-promoter 
plasmid pGL3-DKK4-2kb (a pGL3 basic vector 
with a 2-kb insert starting 2 kb upstream of the 
transcription start site) were also used.
Generating Clones with Stable TFAP2E 
Overexpression
SW480 clones stably overexpressing TFAP2E, and 
control clones using an empty pTarget vector, 
were obtained after transfection with pTFAP2E 
and pTFAP2eFlag by means of a transfection re-
agent (Lipofectamine 2000, Invitrogen) according 
to the manufacturer’s instructions. Stable trans-
fectants were selected through G418 treatment 
(Invitrogen) for 2 weeks. Single colonies were se-
lected and grown further in selective medium. 
TFAP2E expression was assessed by means of 
quantitative RT-PCR.
Transient Transfection and Luciferase Assays
SW480, CACO-2, and HT-29 cells were transfected 
with either a pGL3-DKK4-1kb or pGL3-DKK4-2kb 
vector and pRL-TK as a transfection control (renilla 
luciferase). Transfections were carried out with 
the use of a transfection reagent (Satisfection, 
Agilent). After 3 days, cells were harvested, and 
firefly and renilla luciferase activities were mea-
sured by means of a luminometer (Luciferase Dual 
Reporter Assay, Promega). All experiments were 
repeated independently in triplicate, and all cells 
were seeded in triplicate on the 96-well plates.
Chromatin Immunoprecipitation
Human colorectal-cancer cells were subjected to 
chromatin immunoprecipitation with the use of 
an anti-FLAG antibody (Sigma) according to a 
standard protocol (Upstate Biotechnology) followed 
by genomic real-time quantitative PCR analysis 
of the eluted DNA fragments. Primers were de-
signed to interrogate the promoter regions 1 to 2 kb 
from the transcriptional start site and flanking 
the predicted AP-2 binding sites. Agarose beads 
coupled to either anti-FLAG antibody or control 
IgG were used, and specific and quantitative am-
plification of genomic fragments was performed. 
Cycle-threshold values of immunoprecipitated DNA 
were normalized to cycle-threshold values of in-
put DNA and were presented as the change factor 
relative to the IgG control value.
Immunohistochemical Analysis
Polyclonal antiserum samples were generated 
against human TFAP2E. Rabbits were immu-
nized with the sequence-specific peptide NH2-
HTYSAMERPDGLGAAAGGARC-CONH2. The pep-
tide was custom-synthesized, and the monospecific 
IgG fraction was affinity-purified against the im-
munizing peptide (Pineda). Specificity was tested 
by means of Western blotting and dot-blot analy-
ses, as well as immunohistochemical investigations 
of formalin-fixed and paraffin-embedded sections 
of primary or metastatic colorectal-cancer speci-
mens. Immunostaining was carried out according 
to standard protocols (see the Supplementary 
Appendix).
Microsatellite Instability and Analysis  
of Gene Mutations
Microsatellite instability was analyzed according 
to the recommendation of the National Institutes 
of Health by means of PCR amplification of five 
microsatellite markers: BAT25, BAT26, D2S123, 
D5S346, and D17S250.11 Biochip arrays (Randox 
Laboratory) were used for mutation analysis of 
the relevant colorectal-cancer gene mutations.12
Statistical Analysis
Receiver-operating-characteristic analysis was per-
formed to determine the optimal cutoff value for 
the percentage of methylated reference material. 
Levels of at least 30% were considered to indicate 
hypermethylation, assigned a value of 1, whereas 
levels below 30% were considered to indicate hypo-
methylation, assigned a value of 0. A detailed de-
scription of additional statistical analyses is given 
in the Supplementary Appendix.
R esult s
Frequency of TFAP2E Hypermethylation
Genomic DNA was obtained from samples of 
primary colorectal cancer and adjacent mucosa 
(all snap-frozen) from the 74 patients in the ini-
tial cohort and was analyzed for TFAP2E hyper-
methylation. DNA from 38 of the 74 patients 
(51%) was classified as hypermethylated. None 
of the common clinicopathological characteris-
tics of patients with colorectal cancer — in-
cluding primary tumor site, histologic grade of 
differentiation or stage of cancer, age, or sex 
— correlated with TFAP2E methylation status 
(Table 1).
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TFAP2E Hypermethylation and Gene Expression
Tumor messenger RNA (mRNA) from 28 of the 
74 patients in the initial cohort was analyzed 
for TFAP2E expression by means of RT-PCR. 
Twelve patients showed TFAP2E hypermethyla-
tion and decreased TFAP2E mRNA expression, 
whereas 3 showed hypomethylation and strong 
mRNA expression. The remaining 13 patients 
showed either mRNA expression and hyper-
methylation or no mRNA expression and hypo-
methylation. Furthermore, TFAP2E expression was 
assessed in a group of patients who had tissue 
samples from matched primary cancers and 
metastases. Immunohistochemical evaluation re-
vealed expression of TFAP2E in the cell nuclei; 
cells from both the primary cancers and metas-
tases showed TFAP2E immunoreactivity. No 
difference in expression patterns was noted in 
synchronous and metachronous lesions. Over-
all, there was a trend toward increased expres-
sion in cancers with TFAP2E hypomethylation, 
but significance was not reached, because of the 
limited number of samples (Fig. 1, and the Sup-
plementary Appendix).
DKK4 Targeted by TFAP2E
For the identification of potential down stream 
targets of TFAP2E, SW480-pTFAP2E and SW480-
pTarget cell clones were subjected to micro array 
analysis. The verification of these results by 
means of quantitative real-time PCR confirmed 
DKK4 as the target gene, which was signifi-
cantly down-regulated (on average, to 17% of 
normal expression [range, 33 to 11]) in all sta-
ble SW480-pTFAP2E clones, as compared with 
empty SW480-pTarget vector controls. DKK4 
mRNA levels were then analyzed in nontrans-
fected colorectal-cancer cell lines. SW480 and 
CACO-2 showed strong DKK4 expression that 
was lost on reexpression of TFAP2E through aza-
cytidine treatment (see the Supplementary Ap-
pendix).
Table 1. Characteristics of Patients with Colorectal Cancer Screened for TFAP2E Methylation (Initial Cohort).*
Characteristic
Total  
(N = 74)
TFAP2E 
Hypermethylation 
(N = 38)
TFAP2E 
Hypomethylation 
(N = 36) P Value
Age — yr 67.2±9.7 69.6±9.2 64.8±10.2
Sex — no. (%) 0.81
Male 43 (58) 23 (61) 20 (56)
Female 31 (42) 15 (39) 16 (44)
Grade of differentiation — no./total no. (%) 0.36
G0 or G1 59/64 (92) 30/34 (88) 29/30 (97)
G2 or G3 5/64 (8) 4/34 (12) 1/30 (3)
Localization — no./total no. (%) 0.25
Rectum 19/64 (30) 8/34 (24) 11/30 (37)
Sigmoid colon 19/64 (30) 9/34 (26) 10/30 (33)
Colon 26/64 (41) 17/34 (50) 9/30 (30)
Staging — no./total no. (%) 0.40
T1 or T2 17/64 (27) 11/34 (32) 6/30 (20)
T3 or T4 47/64 (73) 23/34 (68) 24/30 (80)
Lymph nodes involved — no./total no. (%) >0.99
N0 26/64 (41) 14/34 (41) 12/30 (40)
N1 or N2 38/64 (59) 20/34 (59) 18/30 (60)
Metastasis — no./total no. (%) >0.99
M0 59/64 (92) 31/34 (91) 28/30 (93)
M1 5/64 (8) 3/34 (9) 2/30 (7)
* Plus–minus values are means ±SD.
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Effect of TFAP2E Expression 
on Fluorouracil Resistance
Since DKK4 has been implicated in responsive-
ness to chemotherapy,13,14 and our findings showed 
that DKK4 was a downstream target of TFAP2E,
the role of TFAP2E and DKK4 in mediating drug 
resistance in colorectal-cancer cells was assessed 
in vitro. SW480 cells were transiently transfected 
with pTFAP2E or pcDNA3-Dkk4 and treated with 
oxaliplatin, irinotecan, or fluorouracil. The number 
of surviving cells was measured by means of a 3-
(4,5-dimethylthiazol-2-y1)-2,5-diphenyltetrazolium 
A B
DC
FE
Figure 1. Immunohistochemical Evaluation of TFAP2E Expression.
Immunostaining with a polyclonal anti-TFAP2E antibody showed strong, homogeneous staining in the primary tumor 
(Panel A) and corresponding liver metastasis (Panels B and C) or weak or no staining in the primary colon cancer (Panel D) 
and corresponding liver metastasis (Panels E and F). Hepatocytes from the nonneoplastic liver tissue did not express TFAP2E 
(Panels C and F, shown at half the magnification of the other panels; arrows). Hematoxylin was used as a counterstain.
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bromide (MTT) assay. All experiments were per-
formed in triplicate. After 2 and 3 days of expo-
sure to fluorouracil, SW480-pTFAP2E–transfected 
cells showed a significant decrease in survival (of 
about 20% of control values) and SW480 pcDNA3-
Dkk4–transfected cells showed a significant in-
crease in survival (of about 10% of control values), 
respectively (P<0.01 by the Kruskal–Wallis test) 
(Fig. 2A). Cells transfected with both pTFAP2E 
and pcDNA3-Dkk4 had intermediate responsive-
ness. These results were confirmed in SW480-
pTFAP2E clones and SW480-pTarget vector controls 
treated with fluorouracil (P<0.01 by the Mann–
Whitney U test) (Fig. 2B). Similar effects of over-
expressed TFAP2E and DKK4 on cell growth were 
observed in HT29 and DLD1 cells treated with 
increasing concentrations of fluorouracil (see the 
Supplementary Appendix).
TFAP2E Methylation and Chemotherapy 
Resistance
We assessed TFAP2E methylation in four cohorts 
of patients with colorectal cancer undergoing 
chemotherapy or chemoradiation with a f luoro-
uracil-based regimen, to analyze chemoresis-
tance in vivo (Table 2). Cohort I (Bochum) includ-
ed 76 patients who were enrolled in a prospective 
trial comparing the oral fluoropyrimidine cape-
citabine and oxaliplatin (CAPOX) with intravenous 
fluorouracil and oxaliplatin (FUFOX) in patients 
with metastatic colorectal cancer.15 Of the 76 pa-
tients, 74 had samples of enough DNA for methyla-
tion analysis as well as clinical-response data. 
Cohort II (Dresden) consisted of 44 samples from 
patients with metastatic colorectal cancers under-
going fluorouracil–based polychemotherapy (fo-
linic acid [leucovorin], fluorouracil, and irinotecan 
[FOLFIRI] or folinic acid, fluorouracil, and oxali-
platin [FOLFOX]). Of the 44 patients, 43 had suf-
ficient DNA for methylation analysis; of these, 
39 had clinical-response data but 3 stopped che-
motherapy owing to intolerable toxic effects and 
were excluded from the analysis, leaving 36 pa-
tients with data. Cohort III (Mannheim) com-
prised 50 patients with rectal cancer undergoing 
chemoradiation with fluorouracil in combina-
tion with irinotecan and cetuximab. A total of 
49 samples yielded DNA, but matching clinical 
data were available for only 42. Cohort IV (Munich) 
consisted of 70 patients with primary rectal cancer 
who underwent fluorouracil-based chemoradia-
tion8 (i.e., intravenous fluorouracil and 45.0 Gy of 
radiation). Sufficient DNA samples were available 
for 69 patients, 68 of whom had clinical-response 
data.
Table 2 shows the frequencies of TFAP2E hyper-
methylation and response to treatment for each 
cohort. All four cohorts showed a negative asso-
ciation of methylation and treatment response 
(i.e., higher response rates among patients with 
hypomethylated cancers), indicated by a signifi-
cant difference in response rates between pa-
tients with hypomethylation and patients with 
hypermethylation. A substantial effect size was 
estimated for the pooled cohort data (Fig. 3A): 
the treatment-response ratio for hypomethyl-
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Figure 2. Results of Fluorouracil Resistance Assays.
Fluorouracil was used at a dose of 50 μg per milliliter daily for the first 
3 days of experiments involving 50,000 colorectal-cancer cells per well. 
Panel A shows SW480 cells transiently transfected with DKK4-CDS alone, 
TFAP2E-CDS alone, or both; Panel B shows TFAP2E-CDS stable overex-
pressing clones and empty vector controls (four clones per group). Each 
experiment consisted of three independent runs, each conducted in tripli-
cate. I bars indicate means ±SD.
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ation versus hypermethylation was 5.29 (95% 
confidence interval [CI], 2.87 to 9.76). In pa-
tients with metastatic colorectal cancer, tumor 
response was assessed on the basis of RECIST; 
the treatment-response ratio was 7.38 (95% CI, 
2.86 to 19.03). In patients with rectal cancers 
who underwent chemoradiation, treatment re-
sponse was evaluated according to histologic 
response; the response ratio was 5.10 (95% CI, 
2.67 to 9.74). When the cohorts were pooled ac-
cording to response-evaluation criteria (histo-
logic assessment or RECIST), the overall esti-
mated effect was strong, with a response ratio of 
5.74 (95% CI, 3.36 to 9.79) (Fig. 3B).
Discussion
The AP-2 transcription factor family consists of 
five members ― proteins encoded by the tran-
scription factor AP-2 alpha, beta, gamma, delta, 
and epsilon genes TFAP2A, TFAP2B, TFAP2C, 
TFAP2D, and TFAP2E, respectively. These proteins 
can bind to keratin promoters and act as het-
erodimers or homodimers.5 Expression of AP-2 
proteins has been reported in various tissues, no-
tably the breast for TFAP2C and skin for TFAP2E. 
TFAP2A has been shown to be hypermethylated16 
and acts as a tumor suppressor in various can-
cers.17 TFAP2B seems to play a role in diabetes.18 
TFAP2C acts as a tumor suppressor in breast can-
cer19 and may predict tamoxifen resistance 
through its relation to human epidermal growth 
factor receptor type 2 (HER2).20 TFAP2D and 
TFAP2E have also been shown to be hypermethyl-
ated in prostate and colorectal cancer.21
We report that the TFAP2E gene is frequently 
hypermethylated in cancers from patients with 
colorectal cancer, and in these cancers, TFAP2E 
Table 2. TFAP2E Methylation in Four Cohorts of Patients with Colorectal Cancer, According to Response to Treatment.*
Cohort No. and Center
No. of  
Patients Cancer Type
Response  
Evaluation Response Nonresponse P Value
I Bochum 74 Metastatic colorectal cancer RECIST <0.001
Hypermethylated TFAP2E 3 17
Hypomethylated TFAP2E 33 21
II Dresden 36 Metastatic colorectal cancer RECIST <0.001
Hypermethylated TFAP2E 1 22
Hypomethylated TFAP2E 13 0
III Mannheim 42 Primary rectal cancer Histology <0.001
Hypermethylated TFAP2E 5 14
Hypomethylated TFAP2E 20 3
IV Munich 68 Primary rectal cancer Histology <0.001
Hypermethylated TFAP2E 3 28
Hypomethylated TFAP2E 29 8
I and II (combined RECIST) 110 RECIST <0.001
Hypermethylated TFAP2E 4 39
Hypomethylated TFAP2E 46 21
III and IV (combined histology) 110 Histology <0.001
Hypermethylated TFAP2E 8 42
Hypomethylated TFAP2E 49 11
I, II, III, and IV 220 Both <0.001
Hypermethylated TFAP2E 12 81
Hypomethylated TFAP2E 95 32
* P values were calculated with the use of Fisher’s exact test. RECIST denotes Response Evaluation Criteria in Solid 
Tumors (version 1.1)7 (see the Supplementary Appendix, available at NEJM.org).
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mRNA levels are frequently down-regulated. We 
also observed decreased protein expression in 
cancers with increased TFAP2E methylation; 
however, probably owing to the limited number 
of cases in which both expression and methyla-
tion could be analyzed, this association was not 
significant. Nonetheless, the inverse relationship 
between TFAP2E hypermethylation and TFAP2E 
expression in our patients supports the findings 
from our in vitro experiments in which TFAP2E 
expression was induced by azacytidine in colorec-
tal-cancer cells with low or no TFAP2E expression.
To characterize the downstream targets of 
TFAP2E, we performed a microarray analysis of 
TFAP2E-overexpressing cells and found DKK4 to 
be a potential target gene that was significantly 
down-regulated by way of TFAP2E. Further stud-
ies confirmed repression of DKK4 promoter ac-
tivity through TFAP2E and binding of TFAP2E to 
the DKK4 promoter in vitro. DKK4 is a member 
of the dickkopf family, comprising various an-
tagonists of WNT signaling by binding to the 
WNT coreceptor low-density lipoprotein receptor–
related proteins 5 and 6 (LRP5/6).22 DKK4 over-
expression has been observed in the colon mucosa 
of patients with colitis.23 However, the precise 
role of DKK4 in the colon mucosa and its contri-
bution to carcinogenesis are so far unknown. 
Our assessment of DKK4 expression in human 
colorectal cancer specimens and cell lines re-
vealed an inverse expression pattern of TFAP2E 
and DKK4. Despite the complexity of the human 
cancer tissues, which clearly limits the interpre-
tation of expression data, we confirmed this 
inverse expression pattern in a subgroup of pa-
tients with colorectal cancer as well.
Over the past decade, DKK4 has been impli-
cated in fluorouracil resistance in colorectal-
cancer cell lines.13,14 Our in vitro data from cell 
lines treated with fluorouracil confirmed this 
observation. DKK4 overexpression led to in-
creased fluorouracil chemoresistance in colorec-
tal-cancer cell lines, whereas the introduction of 
TFAP2E was associated with increased sensitivity 
to fluorouracil treatment. This in vitro observa-
tion was further supported by the analysis of 
biopsy specimens from patients with colon or 
rectal cancer undergoing fluorouracil-based che-
motherapy or chemoradiation. Tissue samples 
from patients undergoing treatment with fluoro-
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uracil only were not available, since most pa-
tients with colorectal cancer undergo combination 
chemotherapy. Nonetheless, we found a strong 
association between TFAP2E methylation and a 
lack of fluorouracil-based chemotherapy response 
in the tumor in four independent cohorts of 
patients with colorectal cancer. Random-effects 
model analysis of the pooled cohort data re-
vealed that the probability of response to treat-
ment was six times as high among patients with 
hypomethylation as among patients with hyper-
methylation. The correlation was observed in 
primary rectal cancers and metastatic colorectal 
cancers, independent of whether the treatment 
was fluorouracil-based chemotherapy or chemo-
radiation. Also, assessment of response in these 
cohorts, with the use of either standard RECIST 
or histologic-response criteria, did not influence 
this strong association, indicating that TFAP2E 
methylation may be valuable for response pre-
diction in either setting. Since treatment strate-
gies differed across the four cohorts of patients 
with colorectal cancer, alterations of TFAP2E–
DKK4 not only may be associated with fluorouracil 
resistance but also could present a more global 
chemotherapy-resistance marker.
The identification and validation of potential 
genetic and molecular alterations underlying the 
pathogenesis of cancers, and the role of such 
alterations as targets or response predictors in 
various cancers, has been the focus of several re-
search groups.24-26 The molecular mechanisms un-
derlying TFAP2E–DKK4-mediated chemoresistance 
are still unknown. Our studies did not reveal an 
association with genes encoding fluorouracil-
catalyzing enzymes or genes underlying micro-
satellite instability or WNT signaling (see the 
Supplementary Appendix). Further studies will 
be necessary to understand the precise molecu-
lar changes leading to chemoresistance.
Overall, our data indicate that fluorouracil-
based chemotherapy is largely ineffective in pa-
tients with colorectal cancer with TFAP2E hyper-
methylation. Specific targeting of DKK4 in these 
individuals may therefore be an option for over-
coming TFAP2E-mediated chemoresistance.
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